Dark Forest Capital Management LP Has $5.12 Million Stake in Amicus Therapeutics, Inc. $FOLD

Key Points

• Dark Forest Capital Management LP significantly increased its position in Amicus Therapeutics by 1,543.2% during the first quarter, now holding 626,837 shares worth approximately $5.1 million.
• Despite mixed ratings from analysts, the consensus rating for Amicus Therapeutics remains a "Moderate Buy" with a price target of $16.22.
• Amicus Therapeutics' stock is currently trading at $7.59, with a market cap of $2.34 billion, and it has a 12-month price range between $5.51 and $12.65.

Dark Forest Capital Management LP raised its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 1,543.2% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 626,837 shares of the biopharmaceutical company's stock after buying an additional 588,689 shares during the quarter. Dark Forest Capital Management LP owned 0.20% of Amicus Therapeutics worth $5,115,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. PDT Partners LLC increased its stake in Amicus Therapeutics by 110.3% in the 1st quarter. PDT Partners LLC now owns 741,315 shares of the biopharmaceutical company's stock valued at $6,049,000 after buying an additional 388,817 shares during the period. Cubist Systematic Strategies LLC acquired a new position in Amicus Therapeutics in the 1st quarter valued at approximately $4,505,000. Panagora Asset Management Inc. increased its stake in Amicus Therapeutics by 0.7% in the 1st quarter. Panagora Asset Management Inc. now owns 1,444,918 shares of the biopharmaceutical company's stock valued at $11,791,000 after buying an additional 10,641 shares during the period. Vident Advisory LLC acquired a new position in Amicus Therapeutics in the 1st quarter valued at approximately $102,000. Finally, Kodai Capital Management LP acquired a new position in shares of Amicus Therapeutics during the 1st quarter worth $4,938,000.

Amicus Therapeutics Stock Performance

NASDAQ:FOLD traded down $0.03 during midday trading on Friday, reaching $7.99. The stock had a trading volume of 5,558,774 shares, compared to its average volume of 3,714,259. Amicus Therapeutics, Inc. has a 1-year low of $5.51 and a 1-year high of $12.65. The firm's fifty day simple moving average is $6.74 and its 200-day simple moving average is $7.06. The company has a debt-to-equity ratio of 1.92, a current ratio of 3.21 and a quick ratio of 2.29. The stock has a market capitalization of $2.46 billion, a P/E ratio of -66.58 and a beta of 0.55.

Analysts Set New Price Targets

Several research analysts have recently commented on FOLD shares. Wall Street Zen lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, August 30th. Morgan Stanley upgraded shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research note on Thursday, July 17th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, Amicus Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $16.00.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.